Greens Co.,Ltd. (6547.T)
Yokkaichi, JP
Greens Co.,Ltd. is a hospitality group that oversees a network of hotels across Japan. Its portfolio includes approximately 7,000 properties primarily focused on lodging, operating under well-known brand names such as Comfort Hotel, Comfort Inn, and Comfort Suites. Additionally, the company manages other dedicated accommodation sites and urban hotels, featuring brands like Hotel Econo, Green Hotel, City Hotel, Hotel Green Park, and Hotel Espul. The organization was established in 1957 and its main corporate office is situated in Yokkaichi, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.40% | -11.58% | -6.02% | -8.34% | -9.74% | -11.51% | -12.37% | +38.68% | +311.09% | +31.48% | +31.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Travel Lodging: +6.0%+21.2% ★ Q1'26: +8.6% (vs Q1'25)
-
EPS growth Travel Lodging: +9.2%+9.1% Q1'26: +74.2% (vs Q1'25)
-
FCF margin FCF growth · Travel Lodging: +22.6%+11.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Travel Lodging: +18.3%+12.7% Q1'26: +6.5% (vs Q1'25)
-
ROIC Travel Lodging: +5.5%+45.6% ★ Q1'26: +13.1% (vs Q1'25)
-
Share dilution Travel Lodging: +0.0%+0.5% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Travel Lodging: 1.63×1.80× ★ Q1'26: 3.51× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 2 EPS Ana. |
Jun 2027 2 Rev. Ana. 2 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.01B
est: 25.90B (+0.4%)
|
27.14B
est: 28.00B (-3.1%)
|
30.90B
est: 31.40B (-1.6%)
|
22.91B
est: 30.00B (-23.6%)
|
15.71B
est: 19.26B (-18.4%)
|
25.44B
est: 24.50B (+3.8%)
|
36.44B
est: 35.00B (+4.1%)
|
40.97B
est: 41.70B (-1.8%)
|
49.65B
est: 49.15B (+1.0%)
|
55.11B
54.80B – 55.42B
+12.1% YoY
|
58.90B
57.50B – 60.30B
+6.9% YoY
|
62.20B
61.27B – 63.13B
+5.6% YoY
|
| EBITDA |
2.76B
est: -960.32M (+387.9%)
|
2.33B
est: -1.04B (+324.7%)
|
2.90B
est: -1.16B (+349.0%)
|
-2.95B
est: -1.11B (-164.9%)
|
-8.07B
est: -714.12M (-1,030.4%)
|
-1.64B
est: -908.41M (-80.0%)
|
4.26B
est: -1.30B (+428.0%)
|
5.56B
est: -1.55B (+458.6%)
|
6.95B
est: -1.83B (+480.3%)
|
-2.05B
-2.06B – -2.04B
-12.1% YoY
|
-2.19B
-2.24B – -2.14B
-6.9% YoY
|
-2.31B
-2.35B – -2.28B
-5.6% YoY
|
| EBIT |
2.36B
est: -1.45B (+263.2%)
|
1.91B
est: -1.56B (+222.1%)
|
2.43B
est: -1.75B (+238.7%)
|
-3.46B
est: -1.67B (-106.4%)
|
-8.57B
est: -1.08B (-697.4%)
|
-2.16B
est: -1.37B (-57.8%)
|
3.70B
est: -1.95B (+289.2%)
|
5.02B
est: -2.33B (+315.4%)
|
6.31B
est: -2.75B (+329.6%)
|
-3.08B
-3.10B – -3.06B
-12.1% YoY
|
-3.29B
-3.37B – -3.21B
-6.9% YoY
|
-3.48B
-3.53B – -3.42B
-5.6% YoY
|
| Net Income |
1.43B
est: 1.95B (-26.9%)
|
1.19B
est: 1.63B (-27.1%)
|
1.51B
est: 1.67B (-9.4%)
|
-4.33B
est: 160.32M (-2,803.9%)
|
-8.80B
est: -5.47B (-60.8%)
|
-2.18B
est: -2.66B (+18.2%)
|
4.19B
est: 2.51B (+66.9%)
|
4.89B
est: 4.43B (+10.5%)
|
5.26B
est: 4.69B (+12.3%)
|
4.51B
4.17B – 4.85B
-3.8% YoY
|
5.09B
4.95B – 5.23B
+13.0% YoY
|
5.50B
5.39B – 5.60B
+7.9% YoY
|
| SGA |
4.14B
est: 5.38B (-23.1%)
|
4.90B
est: 5.82B (-15.9%)
|
5.49B
est: 6.53B (-15.9%)
|
4.97B
est: 6.23B (-20.3%)
|
4.29B
est: 4.00B (+7.2%)
|
4.59B
est: 5.09B (-9.9%)
|
6.40B
est: 7.27B (-12.0%)
|
8.43B
est: 8.67B (-2.7%)
|
10.15B
est: 10.22B (-0.7%)
|
11.45B
11.39B – 11.52B
+12.1% YoY
|
12.24B
11.95B – 12.53B
+6.9% YoY
|
12.93B
12.73B – 13.12B
+5.6% YoY
|
| EPS |
133.59
est: 141.40 (-5.5%)
|
93.67
est: 118.00 (-20.6%)
|
117.28
est: 120.60 (-2.8%)
|
-336.62
est: 11.60 (-3,001.9%)
|
-683.68
est: -396.10 (-72.6%)
|
-169.20
est: -192.70 (+12.2%)
|
305.33
est: 181.70 (+68.0%)
|
337.98
est: 320.20 (+5.6%)
|
368.87
est: 339.00 (+8.8%)
|
326.20
301.50 – 350.90
-3.8% YoY
|
368.45
358.20 – 378.70
+13.0% YoY
|
397.60
389.85 – 405.35
+7.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 16.9K | 0.30% |
| 2 | Avantis International Small Cap Value ETF AVDV | 0.00% | 687.7K | 0.36% |
| 3 | Dimensional - International Small Cap ETF DFIS | 0.00% | 188.8K | 0.39% |
| 4 | Avantis Responsible International Equity ETF AVSD | 0.00% | 9.1K | 0.23% |
| 5 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.00% | 17.9K | 0.39% |
| 6 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 183.8K | 0.22% |
| 7 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | 170.6K | 0.18% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 86.4K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kenji Shimizu | Senior MD, Head of Business Planning Headquarters & Director | — | male |
| Naoko Suzuki | Head of HR Division & Director | — | female |
| Takahiko Ito | MD & Director | — | male |
| Tomohide Hasegawa | General Manager of Greens Hotels Sales | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6547.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
